Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Moodys
Baxter
Colorcon
AstraZeneca
Mallinckrodt
Johnson and Johnson

Last Updated: October 15, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Theobromine

See Plans and Pricing

« Back to Dashboard

Drug Development Status for Theobromine: Sponsors, patents, clinical trial progress

Theobromine is an investigational drug.

There have been 4 clinical trials for Theobromine. The most recent clinical trial was a Phase 3 trial, which was initiated on April 1st 2015.

The most common disease conditions in clinical trials are Colorectal Neoplasms, Diabetes Mellitus, Type 2, and Cough. The leading clinical trial sponsors are Centre hospitalier de l'Université de Montréal (CHUM), Canadian Institutes of Health Research (CIHR), and Respicopea Limited.

There are two US patents protecting this investigational drug and twenty-one international patents.

Recent Clinical Trials for Theobromine
TitleSponsorPhase
Does Caffeine Reduce Postoperative Bowel Paralysis After Elective Colectomy?Gottfried und Julia Bangerter-Rhyner Foundation, SwitzerlandN/A
Does Caffeine Reduce Postoperative Bowel Paralysis After Elective Colectomy?Thomas SteffenN/A
Evaluation of CYP450 Activities in Diabetic Patients vs. Non-diabetic SubjectsCanadian Institutes of Health Research (CIHR)Phase 4

See all Theobromine clinical trials

Clinical Trial Summary for Theobromine

Top disease conditions for Theobromine
Top clinical trial sponsors for Theobromine

See all Theobromine clinical trials

US Patents for Theobromine

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Theobromine   See Pricing Antiviral drugs for treatment of arenavirus infection Kineta Viral Hemorrhagic Fever, LLC (Seattle, WA)   See Pricing
Theobromine   See Pricing Heterocyclic compounds that inhibit the kinase activity of Mnk useful for treating various cancers eFFECTOR Therapeutics, Inc. (San Diego, CA)   See Pricing
Theobromine   See Pricing Methyl diazepane orexin receptor antagonists Merck Sharp & Dohme Corp. (Rahway, NJ)   See Pricing
Theobromine   See Pricing Inhibitors of HIF prolyl hydroxylase Merck Sharp & Dohme Corp. (Rahway, NJ)   See Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Theobromine

Drugname Country Document Number Estimated Expiration Related US Patent
Theobromine African Regional IP Organization (ARIPO) 3675 2032-02-17   See Pricing
Theobromine Australia 2013221475 2032-02-17   See Pricing
Theobromine Australia 2017200346 2032-02-17   See Pricing
Theobromine Canada 2864484 2032-02-17   See Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
McKesson
Boehringer Ingelheim
Express Scripts
Harvard Business School
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.